Green Thumb Industries (GTBIF) — Coverage Update (v2)

Continuing coverage. Primary sources: FY2025 10-K (filed Feb 25, 2026) and the new Q1 FY2026 10-Q (quarter ended Mar 31, 2026, filed May 6, 2026), both verified via the RoboSystems SEC graph (CIK 0001795139). Price and catalyst status web-verified as of June 22, 2026 (≈$7.33 close). Not investment advice. No price targets.

1. The Hook — what's changed since we covered it

When we initiated on Green Thumb, the story was simple: the most profitable, cleanest-balance-sheet operator in cannabis, trading at $6.67 because nobody on Wall Street is allowed to own it. Six months later the catalyst everyone was waiting for has actually started to fire — and it did almost nothing for Green Thumb. On April 28, 2026 a partial, medical-only Schedule III order took effect. On June 10, Trulieve became the first plant-touching US operator to ring-fence a medical entity and uplist to the NYSE. The sector ripped — the Tier 1 group went from roughly half its 52-week high to about 69%. Green Thumb's stock went along for the ride, to roughly $7.33.

Here's the dissonance. Green Thumb is the best business in the group and it got the least relief, because it's adult-use and retail heavy — exactly the income the medical-only order doesn't touch. Look at the freshest filing: in the first quarter of 2026, the quarter that ended one month before the relief, Green Thumb still carried a 76% effective tax rate. For the full year 2025 it was charged $147 million of income tax on $138 million of operating income, a bill bigger than its core operations earned, and the only reason it still printed a GAAP profit was a non-cash accounting gain. What it actually wired to the IRS was $30 million, and that gap is the second story in this filing. That is the entire thesis in one line: this is a quality compounder whose catalyst hasn't arrived yet. Trulieve's relief is in the numbers now; Green Thumb's is still ahead of it — in broad rescheduling, and in an uplisting of its own.

2. Company Snapshot

Green Thumb Industries is the Chicago-based multi-state operator that runs 113 RISE retail stores across 14 states, supplied by 20 manufacturing facilities and a brand house led by RYTHM — the number-one flower brand in the country — plus Dogwalkers, incredibles, Beboe, Good Green, and the Señorita THC beverage line. It reports in two segments: Retail (~71% of net revenue) and Consumer Packaged Goods (~29%). Founder-CEO Ben Kovler still controls the company through super-voting shares and famously declines to hold quarterly earnings calls — "let the numbers speak." This update is built on those numbers: the FY2025 10-K and the Q1 FY2026 10-Q.

3. The Financial Story

Still growing, still profitable — and now we have a fresh quarter to prove it isn't a one-off. Revenue rose from $893.6 million in FY2021 to $1,175.3 million in FY2025 — roughly 7% compounded through the worst cannabis downturn on record — and Q1 FY2026 revenue grew again, up 7.4% year over year to $300.2 million (from $279.5 million), helped by Minnesota's adult-use launch and store growth. Net income tells the same surface story: $114.2 million for FY2025 and $15.4 million in Q1 FY2026, up 85% from the prior-year quarter. Green Thumb remains the only consistently GAAP-profitable major MSO. That is the part of the story that hasn't changed, and it's why the company belongs at the top of the quality tier.

But read past the headline net income — the operating engine is flat, and the tax code is the reason. Q1 FY2026 operating income was actually down slightly, $40.7 million versus $42.5 million a year earlier; gross margin keeps compressing as mature-market prices fall. The 85% jump in net income wasn't operations — it was a $22.4 million non-operating gain (largely a non-cash warrant fair-value adjustment). The same thing flattered FY2025: reported net income of $114.2 million included roughly $126 million of non-cash warrant gains. Strip those out and the operating picture is a company holding revenue and margin steady against price compression — solid, but not the 85% grower the net-income line implies. The honest read is "durable, lightly growing, heavily over-taxed."

280E is the whole distortion, and it barely moved. In FY2025 Green Thumb reported $263.4 million of pretax income and was charged $147.3 million of income tax — a 55.9% effective rate against the 21% a normal company would pay. The difference, about $92 million a year, is the cost of Section 280E, which bars cannabis companies from deducting ordinary operating expenses because they traffic a Schedule I substance. The most vivid way to see it: 280E taxes gross profit, not net profit, so Green Thumb's $147 million tax charge in FY2025 exceeded its $138 million of operating income. The effective rate has drifted down over time — from a peak of 87% in FY2022 to 63% in FY2024 to 56% in FY2025 as management optimized cost-of-goods allocation (FY2023's reported rate was anomalously low on a one-time deferred-tax benefit and isn't representative). And then Q1 FY2026 snapped right back to 76% — the clearest possible evidence that the April relief, which is medical-only, does essentially nothing for an adult-use-weighted operator.

Cash flow is still the real health signal — with a nuance worth flagging. Green Thumb generated $294.9 million of operating cash flow in FY2025 (against $81.1 million of capex, roughly $214 million of free cash flow) and another $76.0 million of operating cash flow in Q1 FY2026. Cash flow runs well ahead of the messy GAAP line. But look at why it improved, because this is the finding. Green Thumb was charged $147.3 million of income tax in FY2025 and paid $30.2 million of it in cash, down from $130.6 million paid in FY2024. That roughly $100 million reduction in cash tax is very nearly the entire $99.7 million increase in operating cash flow, and the company says as much: the 10-K attributes the improvement "primarily due to lower income taxes paid." The unpaid difference did not disappear. The unrecognized tax benefit reserve went from $76.8 million to $203.3 million in a single year, with a further $22.8 million of accrued interest on top. That is a change in posture, not a change in the business. Through FY2024 Green Thumb had paid its 280E bill nearly in full in cash every year: $148.1 million in 2021, $118.2 million in 2022, $99.5 million in 2023, $130.6 million in 2024. In FY2025 it stopped. That moves it alongside the operators contesting 280E rather than apart from them, and it means roughly $200 million of contested tax now sits on the balance sheet as a two-way option: released if the sector wins, payable if the IRS does.

The balance sheet is the cleanest in the sector — and it got cleaner. Green Thumb ended FY2025 with $274.3 million of cash against $244.9 million of total debt, a net-cash position. By Q1 FY2026 cash had grown to $344.5 million against $289.9 million of debt — still net cash, and still by far the least-levered balance sheet among the billion-dollar MSOs (Curaleaf carries over $900 million of debt). The company keeps buying back stock — roughly 13.4 million shares already repurchased in 2026, on top of $121.8 million since September 2023 — and upsized its credit facility to $200 million in February. Goodwill sits at $592 million (it took its one big $88.5 million impairment back in 2022 and nothing since), intangibles add $437 million, against $2.79 billion of assets. This is a company with the financial flexibility to be a buyer, not a target.

4. Catalyst Scenarios — How the Math Changes

280E relief — the mirror image of Trulieve. This is where Green Thumb's story inverts the one we told about Trulieve. Trulieve is Florida-dominant and essentially medical, so it could deconsolidate adult-use, uplist, and capture outsized relief now. Green Thumb is adult-use and retail heavy, so the April medical-only order is muted for it — which is exactly why its upside is bigger if relief goes broad. Run the full-rescheduling pro forma on FY2025: take the actual $263.4 million of pretax income, apply a normal 21% rate instead of 56%, and tax drops from $147.3 million to about $55 million. Net income goes from $114.2 million to roughly $208 million — an 82% increase without a dollar of new revenue. Adjusted EPS rises from $0.48 to about $0.88. At roughly $7.33 a share, that's about 8 times adjusted earnings for a net-cash, free-cash-flow-positive grower. The catch the bulls must respect: a broad Schedule III order is what unlocks this — and that hearing only begins June 29, 2026.

Uplisting — Green Thumb has the cleanest balance sheet but the harder carve-out. Trulieve proved the path: ring-fence a medical-only entity, deconsolidate adult-use, and clear a major exchange. On pure financial readiness — profitability, net cash, buyback discipline, no impairment overhang — Green Thumb is the most qualified MSO in the group. The wrinkle is structural: because its revenue is adult-use weighted, the medical-only deconsolidation that got Trulieve onto the NYSE is harder to engineer here without carving out the bulk of the business. As of late June 2026, Green Thumb has not announced an uplisting filing or a reverse split — but it did submit DEA registration applications and pick up a conditional Texas license after the Schedule III order, and Kovler called the federal action "a historic step forward." The readiness is there; the structure is the question.

Consolidation — a buyer, not a target. With $344 million of cash, a net-cash balance sheet, and roughly $200 million of free cash flow generation, Green Thumb has the capacity to acquire into a distressed market where weaker operators (AYR wiped out, Cannabist in Chapter 15, Gold Flora in receivership) are forced sellers. Its enterprise value of about $1.7 billion against a $2.79 billion asset base means it's unlikely to be a cheap target — which frames it as the consolidator. The same scarce-capital dynamic that's killing the bottom of the sector is a moat for the top.

Hemp-ban demand migration — the differentiated beverage angle. The federal intoxicating-hemp ban (effective ~November 2026) removes a chunk of unlicensed THC competition. Most MSOs benefit only indirectly. Green Thumb is the rare operator with a direct beverage play: RYTHM/Señorita THC margaritas rolling into 800-plus Circle K locations and the first THC beverage sold at Chicago's United Center (structured intrastate in Illinois). In states that channel hemp demand into licensed dispensaries (CA, IL, NJ), that's incremental revenue, not just a vanished competitor. The lift is state-dependent — ban-only states like Ohio and Texas risk leakage to the illicit market — but Green Thumb is the best-positioned name to actually capture it.

5. Valuation — What It's Worth If It's a Normal Business

Where it trades today. At roughly $7.33, Green Thumb is up about 10% from our v1 price of $6.67 but still about 30% below its 52-week high of $10.43. Market cap is about $1.7 billion; with net cash, enterprise value is also around $1.7 billion — roughly 5 times FY2025 normalized EBITDA of $348 million and about 1.4 times revenue. Those are the cheapest multiples of any healthy consumer business in public markets, and the discount is almost entirely the Schedule I / OTC penalty.

Cross-sector re-rating. The comparison the market refuses to make: Green Thumb trades at ~5x EV/EBITDA while consumer-staples and health-and-wellness peers trade far higher — Constellation Brands at roughly 12x, the broader CPG/health cohort generally in a 10–14x band. Apply a deliberately conservative 8–12x to Green Thumb's $348 million of EBITDA and enterprise value lands around $2.8 billion to $4.2 billion; add the net cash and that's an implied equity value roughly in the low-to-high teens per share, versus about $7.30 today. The point isn't a target — it's that today's ~5x multiple is the market pricing in permanent Schedule I status. Any move toward "normal company" treatment closes a large part of that gap.

DCF, scenario-ranged. A base case that assumes 280E persists indefinitely — free cash flow around $200 million growing low-single-digits, discounted at an elevated 13–15% WACC appropriate for a Schedule I OTC name, with conservative ~2–3% terminal growth — supports a value not far from today's price; the market is, roughly, correctly pricing a company stuck in the current regime. A rescheduling case changes two inputs at once: steady-state free cash flow steps up by the ~$90 million annual 280E saving, and the discount rate compresses as exchange access and institutional ownership de-risk the equity. Those two effects compound, which is why the catalyst case widens the band toward the cross-sector range above. Framing: implied value under stated assumptions, not a price target, not advice.

6. Risks and Open Questions

The catalyst is real but not guaranteed, and the calendar is the risk. The broad-rescheduling hearing only begins June 29, 2026 and runs into mid-July; the partial medical-only order is itself under a pending D.C. Circuit challenge, and there is organized political opposition. If broad Schedule III stalls into 2027, Green Thumb keeps absorbing ~$92 million a year of excess tax charge with no relief — and unlike medical-heavy peers, it gets almost nothing from the partial order in the meantime. Operationally, the margin story is the live concern: gross margin keeps compressing, Illinois (its largest market) saw adult-use revenue fall ~12.5% in 2025 on price compression, and same-store sales were negative. Green Thumb is also one of the nine MSOs named in the February 2026 Ohio AG antitrust suit alleging price-fixing — live legal risk across the group. And its back-tax exposure is no longer the small one this coverage previously described: the contested reserve reached $203.3 million at year-end 2025, up from $76.8 million, and a prospective fix does not erase it. The honest version: a great operator, in a still-broken regulatory regime, whose stock now embeds a bit more optimism than it did six months ago.

7. The Bottom Line

Green Thumb is the quality compounder of US cannabis — the most profitable operator, the cleanest balance sheet, a buyer not a target — and it's the clearest example of a company whose catalyst hasn't arrived. The April relief was medical-only, and Green Thumb is adult-use weighted, so its most recent quarter still carried a 76% effective tax rate. Trulieve already monetized its catalyst by uplisting; Green Thumb's is still in front of it. If broad rescheduling lands, 280E relief alone takes adjusted earnings from $114 million toward $208 million and the stock sits at roughly 8 times those earnings — before any re-rating toward the 10–14x multiples normal consumer businesses command. If it doesn't, you still own the best-run, best-capitalized operator in the sector, buying back its own stock while it waits. Watch three things: the June 29 DEA hearing and the D.C. Circuit stay, any Green Thumb move toward a medical-only uplisting structure, and Illinois pricing. The data is all here. What you do with it is your call.

---

Built with RoboSystems — structured SEC/XBRL filing data for every public company: https://robosystems.ai. New customers get 50% off your first month with code CANNABIS50.